v3.25.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 269,907 $ 322,399
Accounts receivable, net 27,882 38,520
Inventory 46,667 50,082
Prepaid expenses and other current assets 15,305 18,145
Total current assets 359,761 429,146
Property and equipment, net 162,727 164,474
Goodwill 129,429 159,878
Intangible assets, net 193,066 194,957
Other assets 51,983 59,789
Total assets 896,966 1,008,244
Current liabilities:    
Accounts payable 11,525 11,957
Accrued expenses and other current liabilities 50,202 36,407
Deferred revenue 1,639 2,375
Current portion of long-term debt 5,440 5,440
Current portion of finance lease liabilities 876 792
Total current liabilities 69,682 56,971
Long-term debt, less current portion 288,436 290,492
Finance lease liabilities, less current portion 30,651 31,106
Deferred tax liabilities 2,028 11
Other long-term liabilities 38,186 52,455
Total liabilities 428,983 431,035
Commitments and contingencies (Note 7)
Stockholders’ equity:    
Additional paid-in capital 191,377 181,874
Retained earnings 71,355 140,891
Accumulated other comprehensive income 574 0
Total stockholders’ equity attributable to Maravai LifeSciences Holdings, Inc. 265,859 325,292
Non-controlling interest 202,124 251,917
Total stockholders’ equity 467,983 577,209
Total liabilities and stockholders’ equity 896,966 1,008,244
Class A Common Stock    
Stockholders’ equity:    
Common stock 1,446 1,420
Class B Common Stock    
Stockholders’ equity:    
Common stock $ 1,107 $ 1,107